Sanofi/GlaxoSmithKline Covid-19 vaccine enters final trials

The firms have launched a large phase 3 trial enrolling 35,000 adult volunteers (Andrew Matthews/PA)

Production of another potential vaccine against Covid-19 will begin within weeks, its developers Sanofi and GlaxoSmithKline said.

They have launched a large phase 3 trial enrolling 35,000 adult volunteers in the United States, Asia, Africa and Latin America.